RenovoRx filed an amended 8-K to correct a hyperlink in its May 12, 2026 filing; no substantive changes were made. The underlying report disclosed second quarter 2026 financial results and raised full-year revenue guidance to $3.75 million–$4.25 million from $3.0 million–$4.0 million. Second-quarter revenue reached $909,000, a 61% sequential increase, with gross margin at approximately 84%. The company reported a net loss of $2.9 million and ended the quarter with $9.5 million in cash. Commercially, RenovoRx added five active cancer center customers to reach 21, while its Phase III TIGeR-PaC trial achieved full enrollment. RenovoRx operates in the life sciences industry, developing targeted oncology therapies and commercializing a drug-delivery device.
